These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 19067373)

  • 1. Randomized, controlled trial of miglustat in Gaucher's disease type 3.
    Schiffmann R; Fitzgibbon EJ; Harris C; DeVile C; Davies EH; Abel L; van Schaik IN; Benko W; Timmons M; Ries M; Vellodi A
    Ann Neurol; 2008 Nov; 64(5):514-22. PubMed ID: 19067373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM; Barnett NL; Kolodny EH
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.
    Elstein D; Dweck A; Attias D; Hadas-Halpern I; Zevin S; Altarescu G; Aerts JF; van Weely S; Zimran A
    Blood; 2007 Oct; 110(7):2296-301. PubMed ID: 17609429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term effect of miglustat in every day clinical use in treatment-naïve or previously treated patients with type 1 Gaucher's disease.
    Giraldo P; Latre P; Alfonso P; Acedo A; Alonso D; Barez A; Corrales A; Franco R; Roldan V; Serrano S; Pocovi M
    Haematologica; 2006 May; 91(5):703-6. PubMed ID: 16627252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
    Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
    Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
    Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A
    J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective treatment of an elderly patient with Gaucher's disease and Parkinsonism: a case report of 24 months' oral substrate reduction therapy with miglustat.
    Hughes DA; Ginsberg L; Baker R; Goodwin S; Milligan A; Richfield L; Mehta AB
    Parkinsonism Relat Disord; 2007 Aug; 13(6):365-8. PubMed ID: 17049454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
    Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
    J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twelve years of experience with miglustat in the treatment of type 1 Gaucher disease: The Spanish ZAGAL project.
    Giraldo P; Andrade-Campos M; Alfonso P; Irun P; Atutxa K; Acedo A; Barez A; Blanes M; Diaz-Morant V; Fernández-Galán MA; Franco R; Gil-Cortes C; Giner V; Ibañez A; Latre P; Loyola I; Luño E; Hernández-Martin R; Medrano-Engay B; Puerta J; Roig I; de la Serna J; Salamero O; Villalón L; Pocovi M
    Blood Cells Mol Dis; 2018 Feb; 68():173-179. PubMed ID: 27836529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM; Elstein D; Hrebícek M; Zimran A
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Miglustat.
    McCormack PL; Goa KL
    Drugs; 2003; 63(22):2427-34; discussion 2435-6. PubMed ID: 14609352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Miglustat: new drug. In type 1 Gaucher's disease : a slight benefit after imiglucerase therapy.
    Prescrire Int; 2005 Oct; 14(79):168-70. PubMed ID: 16285070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
    Giraldo P; Alfonso P; Atutxa K; Fernández-Galán MA; Barez A; Franco R; Alonso D; Martin A; Latre P; Pocovi M
    Haematologica; 2009 Dec; 94(12):1771-5. PubMed ID: 19608672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
    Cox T; Lachmann R; Hollak C; Aerts J; van Weely S; Hrebícek M; Platt F; Butters T; Dwek R; Moyses C; Gow I; Elstein D; Zimran A
    Lancet; 2000 Apr; 355(9214):1481-5. PubMed ID: 10801168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
    Amato D; Patterson MA
    J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study.
    Patterson MC; Vecchio D; Prady H; Abel L; Wraith JE
    Lancet Neurol; 2007 Sep; 6(9):765-72. PubMed ID: 17689147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term miglustat therapy in children with Niemann-Pick disease type C.
    Patterson MC; Vecchio D; Jacklin E; Abel L; Chadha-Boreham H; Luzy C; Giorgino R; Wraith JE
    J Child Neurol; 2010 Mar; 25(3):300-5. PubMed ID: 19822772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
    Cox TM; Amato D; Hollak CE; Luzy C; Silkey M; Giorgino R; Steiner RD;
    Orphanet J Rare Dis; 2012 Dec; 7():102. PubMed ID: 23270487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
    Hollak CE; Hughes D; van Schaik IN; Schwierin B; Bembi B
    Pharmacoepidemiol Drug Saf; 2009 Sep; 18(9):770-7. PubMed ID: 19507165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.